{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:59:50Z","timestamp":1783947590899,"version":"3.55.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.medj.2026.101077","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T03:49:28Z","timestamp":1775533768000},"page":"101077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of phase 2\u20133 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6571-9874","authenticated-orcid":false,"given":"Tsubasa","family":"Tsutsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Shu Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Apoorva","family":"Sasikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn Jun Kit","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Kai","family":"Tioh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanawin","family":"Pramotedham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvakumar","family":"Vigneshwaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Jin Sun","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Yock","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"Le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101077_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib9","article-title":"Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples","volume":"358","author":"Riley","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2026.101077_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2026.101077_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib13","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101077_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib25","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib28","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2026.101077_bib31","article-title":"Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study","author":"Sun","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib32","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib33","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","article-title":"Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"8","author":"Noureddin","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib35","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.medj.2026.101077_bib36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3350\/cmh.2025.0145","article-title":"HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study","volume":"31","author":"Wong","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib37","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101077_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101077_bib39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hepr.13695","article-title":"Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study","volume":"51","author":"Okanoue","year":"2021","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.medj.2026.101077_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib46","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib47","article-title":"Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2026.101077_bib48","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2026.101077_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib52","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib53","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib57","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.70038","article-title":"Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH","volume":"61","author":"Raji","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101077_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib60","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib61","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib65","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial","volume":"31","author":"Noureddin","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101077_bib67","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2026.101077_bib68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib69","article-title":"Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial","author":"Xue","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib70","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","article-title":"High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysis","volume":"23","author":"Ho","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib71","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.32315","article-title":"Placebo effect on progression and regression in NASH: Evidence from a meta-analysis","volume":"75","author":"Ng","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib72","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101077_bib73","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical Trial Landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib74","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cmet.2024.04.016","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.medj.2026.101077_bib75","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101077_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12734","article-title":"Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials","volume":"15","author":"Horn","year":"2025","journal-title":"Clin. Obes."},{"key":"10.1016\/j.medj.2026.101077_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.medj.2026.101077_bib78","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.medj.2026.101077_bib79","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41574-025-01125-9","article-title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","volume":"21","author":"Walker","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.medj.2026.101077_bib80","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: Insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib81","first-page":"611","article-title":"Insights Into Combination Therapy for Metabolic Dysfunction-Associated Steatohepatitis","volume":"20","author":"Charlton","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib82","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.numecd.2022.07.001","article-title":"Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis","volume":"32","author":"Pennisi","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.medj.2026.101077_bib83","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and\/or Type 2 Diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2026.101077_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2026.101077_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33326","article-title":"One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice","volume":"7","author":"Gasoyan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2026.101077_bib86","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12916-025-04200-0","article-title":"Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications","volume":"23","author":"Wu","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.medj.2026.101077_bib87","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/d41586-025-03711-3","article-title":"CRISPR vs cholesterol: can gene editing prevent heart disease?","volume":"647","author":"Ledford","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101077_bib88","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib89","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","article-title":"The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained","volume":"20","author":"Rowe","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib90","article-title":"Placebo Rates in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis","volume":"4","author":"Idalsoaga","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s41669-022-00370-2","article-title":"Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis","volume":"7","author":"Javanbakht","year":"2023","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.medj.2026.101077_bib92","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101077_bib93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.14309\/ajg.0000000000002042","article-title":"Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants","volume":"118","author":"Tay","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.medj.2026.101077_bib94","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2026.101077_bib95","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medj.2026.101077_bib96","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HEP.0000000000001028","article-title":"Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis","volume":"83","author":"Koh","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib98","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101077_bib99","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.31624","article-title":"MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101077_bib101","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101077_bib102","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.medj.2026.101077_bib103","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2026.101077_bib104","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11135-018-0802-x","article-title":"Fixed and random effects models: making an informed choice","volume":"53","author":"Bell","year":"2019","journal-title":"Qual. Quant."},{"key":"10.1016\/j.medj.2026.101077_bib105","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2023"},{"key":"10.1016\/j.medj.2026.101077_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.medj.2026.101077_bib107","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 11: Undertaking network meta-analyses","author":"Chaimani","year":"2024"},{"key":"10.1016\/j.medj.2026.101077_bib108","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res. Synth. Methods"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:09:18Z","timestamp":1778252958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666634026000802"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101077","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of phase 2\u20133 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101077"}}